The Cooper Companies, Inc. (COO) 10-Year Financial Performance & Capital Metrics

COO • • Industrial / General

HealthcareMedical InstrumentsOphthalmic Devices & Vision CareContact Lenses & Vision Correction

AboutThe Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.Show more

Revenue $4.09B +5.1%
EBITDA $1.11B +2.3%
Net Income $375M -4.4%
EPS (Diluted) 1.87 -4.6%
Gross Margin 60.67% -9.0%
EBITDA Margin 27.02% -2.6%
Operating Margin 16.69% -7.9%
Net Margin 9.16% -9.0%
ROE 4.59% -8.5%
ROIC 4.77% -7.3%
Debt/Equity 0.34 +5.7%
Interest Coverage 6.83 +10.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 11.0%
✓Healthy 5Y average net margin of 28.0%

✗Weaknesses

✗Weak 3Y average ROE of 4.5%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y8.58%

5Y10.98%

3Y7.35%

TTM6.35%

Profit (Net Income) CAGR

10Y6.3%

5Y9.48%

3Y-0.95%

TTM13.5%

EPS CAGR

10Y-7.64%

5Y-17.22%

3Y-1.22%

TTM13.24%

ROCE

10Y Avg7.22%

5Y Avg5.96%

3Y Avg5.86%

Latest6.05%

Peer Comparison

Contact Lenses & Vision Correction

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COOThe Cooper Companies, Inc.	16.13B	82.31	44.02	5.06%	10.08%	4.88%	2.69%	0.34
LUCYInnovative Eyewear, Inc.	8.19M	1.53	-0.29	41.99%	-770.01%	-17.97%
BLCOBausch + Lomb Corporation	6.18B	17.44	-19.38	15.56%	-6.13%	-4.69%		0.75
STAASTAAR Surgical Company	1.04B	20.97	-51.15	-2.64%	-41.79%	-27.24%		0.10
WRBYWarby Parker Inc.	3B	28.33	-166.65	15.16%	0.08%	0.19%	1.16%	0.66

Profit & Loss

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Sales/Revenue+	1.97B	2.14B	2.53B	2.65B	2.43B	2.92B	3.31B	3.59B	3.9B	4.09B
Revenue Growth %	0.09%	0.09%	0.18%	0.05%	-0.08%	0.2%	0.13%	0.09%	0.08%	0.05%
Cost of Goods Sold+	793.7M	773.2M	900.5M	896.6M	896.1M	966.7M	1.17B	1.24B	1.3B	1.61B
COGS % of Revenue	0.4%	0.36%	0.36%	0.34%	0.37%	0.33%	0.35%	0.34%	0.33%	0.39%
Gross Profit+	1.17B	1.37B	1.63B	1.76B	1.53B	1.96B	2.14B	2.36B	2.6B	2.48B
Gross Margin %	0.6%	0.64%	0.64%	0.66%	0.63%	0.67%	0.65%	0.66%	0.67%	0.61%
Gross Profit Growth %	0.1%	0.16%	0.2%	0.08%	-0.13%	0.27%	0.09%	0.1%	0.1%	-0.04%
Operating Expenses+	849M	936.7M	1.2B	1.23B	1.22B	1.45B	1.63B	1.82B	1.89B	1.8B
OpEx % of Revenue	0.43%	0.44%	0.48%	0.46%	0.5%	0.5%	0.49%	0.51%	0.49%	0.44%
Selling, General & Admin	722.8M	799.1M	973.3M	996.6M	992.5M	1.21B	1.34B	1.5B	1.53B	1.63B
SG&A % of Revenue	0.37%	0.37%	0.38%	0.38%	0.41%	0.41%	0.41%	0.42%	0.39%	0.4%
Research & Development	65.4M	69.2M	84.8M	86.7M	93.3M	92.7M	110.3M	137.4M	155.1M	172.2M
R&D % of Revenue	0.03%	0.03%	0.03%	0.03%	0.04%	0.03%	0.03%	0.04%	0.04%	0.04%
Other Operating Expenses	60.8M	68.4M	146.7M	145.8M	137.2M	146.1M	179.5M	186.2M	201.2M	0
Operating Income+	324.1M	429.1M	403.1M	546.7M	311.8M	505.8M	507.6M	533.1M	705.7M	682.9M
Operating Margin %	0.16%	0.2%	0.16%	0.21%	0.13%	0.17%	0.15%	0.15%	0.18%	0.17%
Operating Income Growth %	0.37%	0.32%	-0.06%	0.36%	-0.43%	0.62%	0%	0.05%	0.32%	-0.03%
EBITDA+	522.4M	617.5M	678.2M	827.5M	598.9M	815.1M	853.7M	900.8M	1.08B	1.11B
EBITDA Margin %	0.27%	0.29%	0.27%	0.31%	0.25%	0.28%	0.26%	0.25%	0.28%	0.27%
EBITDA Growth %	0.22%	0.18%	0.1%	0.22%	-0.28%	0.36%	0.05%	0.06%	0.2%	0.02%
D&A (Non-Cash Add-back)	198.3M	188.4M	275.1M	280.8M	287.1M	309.3M	346.1M	367.7M	375.1M	423M
EBIT	321.8M	427.4M	414.6M	545.4M	303.3M	514.6M	532.6M	518.2M	696.6M	630.4M
Net Interest Income+	-26.2M	-33.4M	-82.7M	-68M	-36.8M	-23.1M	-57.3M	-105.3M	-114.3M	-100M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	26.19M	33.4M	82.7M	68M	36.8M	23.1M	57.3M	105.3M	114.3M	100M
Other Income/Expense	-28.5M	-35.1M	-71.2M	-91.4M	-45.3M	-14.3M	-32.3M	-120.2M	-123.4M	-116.4M
Pretax Income+	295.63M	394M	331.9M	477.4M	266.5M	491.5M	475.3M	412.9M	582.3M	566.5M
Pretax Margin %	0.15%	0.18%	0.13%	0.18%	0.11%	0.17%	0.14%	0.11%	0.15%	0.14%
Income Tax+	20.7M	21.1M	192M	10.7M	28.1M	-2.45B	89.5M	118.7M	190M	191.6M
Effective Tax Rate %	0.93%	0.95%	0.42%	0.98%	0.89%	5.99%	0.81%	0.71%	0.67%	0.66%
Net Income+	273.92M	372.9M	139.9M	466.7M	238.4M	2.94B	385.8M	294.2M	392.3M	374.9M
Net Margin %	0.14%	0.17%	0.06%	0.18%	0.1%	1.01%	0.12%	0.08%	0.1%	0.09%
Net Income Growth %	0.35%	0.36%	-0.62%	2.34%	-0.49%	11.35%	-0.87%	-0.24%	0.33%	-0.04%
Net Income (Continuing)	274.9M	372.9M	139.9M	466.7M	238.4M	2.94B	385.8M	294.2M	392.3M	374.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	168K	100K	200K	200K	200K	200K	200K	200K	200K	200K
EPS (Diluted)+	5.59	7.52	2.81	9.32	4.81	59.07	1.94	1.48	1.96	1.87
EPS Growth %	0.35%	0.35%	-0.63%	2.32%	-0.48%	11.28%	-0.97%	-0.24%	0.32%	-0.05%
EPS (Basic)	5.65	7.63	2.85	9.47	4.86	59.73	1.96	1.49	1.97	1.87
Diluted Shares Outstanding	49M	49.6M	49.7M	50.05M	49.55M	49.85M	198.8M	199.2M	200.4M	200M
Basic Shares Outstanding	48.5M	48.9M	49.1M	49.3M	49.1M	49.3M	197.2M	198M	198.9M	200M
Dividend Payout Ratio	0.01%	0.01%	0.02%	0.01%	0.01%	0%	0.01%	0.01%	-	-

Balance Sheet

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Total Current Assets+	934.46M	953.2M	1.09B	1.16B	1.27B	1.47B	1.53B	1.7B	1.95B	2.11B
Cash & Short-Term Investments	100.8M	88.8M	77.7M	89M	115.9M	95.9M	138.2M	120.8M	107.6M	110.6M
Cash Only	100.8M	88.8M	77.7M	89M	115.9M	95.9M	138.2M	120.8M	107.6M	110.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	291.4M	316.6M	374.7M	435.3M	435.4M	515.3M	557.8M	609.7M	717M	829M
Days Sales Outstanding	54.08	54.02	54	59.88	65.38	64.36	61.54	61.93	67.18	73.94
Inventory	417.7M	454.1M	468.8M	506.9M	570.4M	585.6M	628.7M	735.6M	802.7M	846M
Days Inventory Outstanding	192.09	214.36	190.02	206.36	232.34	221.11	196.33	217.35	225.43	191.85
Other Current Assets	49.7M	0	0	0	0	89.2M	0	238.8M	324.2M	320.8M
Total Non-Current Assets+	3.54B	3.91B	5.02B	5.11B	5.46B	8.14B	9.96B	9.95B	10.36B	10.29B
Property, Plant & Equipment	877.7M	910.1M	976M	1.13B	1.54B	1.35B	1.43B	1.63B	1.86B	2.08B
Fixed Asset Turnover	2.24x	2.35x	2.60x	2.34x	1.58x	2.17x	2.31x	2.20x	2.09x	1.97x
Goodwill	2.16B	2.35B	2.39B	2.43B	2.45B	2.57B	3.61B	3.62B	3.84B	3.85B
Intangible Assets	441.09M	504.7M	1.52B	1.41B	1.29B	1.27B	1.89B	1.71B	1.79B	1.59B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	51.9M	75.6M	74.1M	66.8M	104.8M	401.2M	587.9M	637.1M	660.6M	689.2M
Total Assets+	4.48B	4.86B	6.11B	6.27B	6.74B	9.61B	11.49B	11.66B	12.32B	12.39B
Asset Turnover	0.44x	0.44x	0.41x	0.42x	0.36x	0.30x	0.29x	0.31x	0.32x	0.33x
Asset Growth %	0%	0.09%	0.26%	0.03%	0.07%	0.43%	0.2%	0.01%	0.06%	0.01%
Total Current Liabilities+	536.46M	396.1M	536.5M	1.11B	1B	732.1M	1.28B	969M	1.02B	1.11B
Accounts Payable	107.4M	142.1M	146.4M	150.1M	176M	161.4M	248.8M	261.9M	260.5M	300.4M
Days Payables Outstanding	49.39	67.08	59.34	61.1	71.69	60.94	77.7	77.38	73.16	68.12
Short-Term Debt	226.3M	23.4M	37.1M	563.7M	409.3M	82.9M	395.7M	44.4M	32.2M	85.6M
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	209.5M	230.6M	353M	396.8M	385.8M	468.3M	525.2M	538.1M	599.1M	388.3M
Current Ratio	1.74x	2.41x	2.03x	1.05x	1.27x	2.00x	1.20x	1.76x	1.91x	1.89x
Quick Ratio	0.96x	1.26x	1.16x	0.59x	0.70x	1.20x	0.71x	1.00x	1.12x	1.13x
Cash Conversion Cycle	196.77	201.31	184.68	205.13	226.02	224.52	180.18	201.9	219.45	197.67
Total Non-Current Liabilities+	1.24B	1.29B	2.27B	1.54B	1.91B	1.93B	3.04B	3.14B	3.21B	3.04B
Long-Term Debt	1.11B	1.15B	1.99B	1.26B	1.38B	1.4B	2.35B	2.52B	2.55B	2.46B
Capital Lease Obligations	0	0	0	0	236.8M	1.5M	3.7M	3.4M	2.4M	242.3M
Deferred Tax Liabilities	37.53M	38.8M	31M	28M	25.8M	24.1M	149.9M	101.5M	96M	93.3M
Other Non-Current Liabilities	94.6M	98.7M	251.8M	244.7M	261.8M	510.3M	338.4M	329.4M	369.1M	49.8M
Total Liabilities	1.78B	1.68B	2.81B	2.65B	2.91B	2.66B	4.32B	4.11B	4.23B	4.16B
Total Debt+	1.33B	1.17B	2.02B	1.83B	2.06B	1.48B	2.76B	2.57B	2.58B	2.78B
Net Debt	1.23B	1.08B	1.95B	1.74B	1.95B	1.39B	2.63B	2.45B	2.48B	2.67B
Debt / Equity	0.49x	0.37x	0.61x	0.50x	0.54x	0.21x	0.39x	0.34x	0.32x	0.34x
Debt / EBITDA	2.55x	1.90x	2.98x	2.21x	3.45x	1.82x	3.24x	2.85x	2.39x	2.52x
Net Debt / EBITDA	2.36x	1.76x	2.87x	2.10x	3.25x	1.70x	3.08x	2.72x	2.29x	2.42x
Interest Coverage	12.37x	12.85x	4.87x	8.04x	8.47x	21.90x	8.86x	5.06x	6.17x	6.83x
Total Equity+	2.7B	3.18B	3.31B	3.63B	3.82B	6.94B	7.17B	7.55B	8.08B	8.24B
Equity Growth %	0.01%	0.18%	0.04%	0.1%	0.05%	0.81%	0.03%	0.05%	0.07%	0.02%
Book Value per Share	55.02	64.03	66.56	72.50	77.19	139.26	36.09	37.91	40.34	41.20
Total Shareholders' Equity	2.7B	3.18B	3.31B	3.63B	3.82B	6.94B	7.17B	7.55B	8.08B	8.24B
Common Stock	5.2M	5.2M	5.3M	5.3M	5.3M	5.4M	5.4M	21.6M	21.7M	21.8M
Retained Earnings	2.05B	2.43B	2.58B	3.03B	3.26B	6.2B	6.58B	6.88B	7.27B	7.64B
Treasury Stock	-360.1M	-415.1M	-415.1M	-571.2M	-617.3M	-639.6M	-714.5M	-710.3M	-706M	-995.2M
Accumulated OCI	-489.6M	-375.3M	-430.7M	-447.1M	-472M	-341.3M	-466.8M	-453.8M	-421.7M	-406.5M
Minority Interest	168K	100K	200K	200K	200K	200K	200K	200K	200K	200K

Cash Flow

	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Cash from Operations+	509.64M	593.6M	668.9M	713.2M	486.6M	738.6M	692.4M	607.5M	709.3M	796.1M
Operating CF Margin %	0.26%	0.28%	0.26%	0.27%	0.2%	0.25%	0.21%	0.17%	0.18%	0.19%
Operating CF Growth %	0.3%	0.16%	0.13%	0.07%	-0.32%	0.52%	-0.06%	-0.12%	0.17%	0.12%
Net Income	274.93M	372.9M	139.9M	466.7M	238.4M	2.94B	385.8M	294.2M	392.3M	374.9M
Depreciation & Amortization	198.27M	188.4M	275.1M	280.8M	287.1M	309.3M	346.1M	367.7M	375.1M	377.4M
Stock-Based Compensation	29.86M	37.2M	43.2M	35.1M	37.6M	43.8M	54.2M	62.1M	75.1M	70.5M
Deferred Taxes	-10.72M	-7.1M	2.9M	-15.9M	-900K	-2.5B	53.9M	44.7M	118.9M	135.2M
Other Non-Cash Items	13.37M	8.4M	88.2M	-13.4M	50.2M	92.9M	26.4M	57.6M	81.6M	-161.9M
Working Capital Changes	3.93M	-6.2M	119.6M	-40.1M	-125.8M	-149.9M	-174M	-218.8M	-333.7M	0
Change in Receivables	1.65M	-25.1M	-59.5M	-55.6M	8.5M	-75.5M	-33.8M	-60.2M	-117.1M	-120.3M
Change in Inventory	12.25M	-30.9M	-5M	-37.3M	-62.3M	-9.2M	-40.4M	-105.4M	-59.3M	-46M
Change in Payables	-10.46M	25M	2.9M	3.6M	23.2M	-16M	49.9M	5.5M	9.3M	8M
Cash from Investing+	-418.78M	-381.3M	-1.52B	-351.3M	-364.5M	-450.3M	-1.83B	-449M	-764.6M	-372.9M
Capital Expenditures	-152.64M	-127.2M	-193.6M	-292.1M	-310.4M	-214.4M	-242M	-392.5M	-421.2M	-362.4M
CapEx % of Revenue	0.08%	0.06%	0.08%	0.11%	0.13%	0.07%	0.07%	0.11%	0.11%	0.09%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-266.1M	-254.1M	-1.32B	-59.2M	-54.1M	-235.9M	0	0	0	0
Cash from Financing+	-1.38M	-227.9M	844.4M	-351.4M	-95.5M	-311.4M	1.19B	-173.9M	39.2M	-425.9M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.91M	-2.9M	-2.9M	-3M	-3M	-3M	-3M	-3M	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	16.5M	-7.5M	-2.3M	-400K	-4.1M	0	-3.6M	9.9M	-30.3M	-425.9M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	357M	466.4M	475.3M	421.1M	176.2M	524.2M	450.4M	215M	288.1M	433.7M
FCF Margin %	0.18%	0.22%	0.19%	0.16%	0.07%	0.18%	0.14%	0.06%	0.07%	0.11%
FCF Growth %	1.41%	0.31%	0.02%	-0.11%	-0.58%	1.98%	-0.14%	-0.52%	0.34%	0.51%
FCF per Share	7.29	9.40	9.56	8.41	3.56	10.52	2.27	1.08	1.44	2.17
FCF Conversion (FCF/Net Income)	1.86x	1.59x	4.78x	1.53x	2.04x	0.25x	1.79x	2.06x	1.81x	2.12x
Interest Paid	23.7M	31.3M	82.1M	75.3M	46.5M	28.4M	49.1M	117.5M	134.8M	0
Taxes Paid	29.4M	15.6M	18.8M	39.2M	51.1M	63.2M	66.6M	67.8M	78.4M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	10.2%	12.7%	4.32%	13.46%	6.4%	54.7%	5.47%	4%	5.02%	4.59%
Return on Invested Capital (ROIC)	6.13%	7.86%	6.36%	7.72%	4.2%	5.38%	4.2%	4.04%	5.15%	4.77%
Gross Margin	59.64%	63.85%	64.45%	66.21%	63.14%	66.92%	64.67%	65.62%	66.64%	60.67%
Net Margin	13.93%	17.43%	5.52%	17.59%	9.81%	100.76%	11.66%	8.19%	10.07%	9.16%
Debt / Equity	0.49x	0.37x	0.61x	0.50x	0.54x	0.21x	0.39x	0.34x	0.32x	0.34x
Interest Coverage	12.37x	12.85x	4.87x	8.04x	8.47x	21.90x	8.86x	5.06x	6.17x	6.83x
FCF Conversion	1.86x	1.59x	4.78x	1.53x	2.04x	0.25x	1.79x	2.06x	1.81x	2.12x
Revenue Growth	9.45%	8.75%	18.41%	4.76%	-8.39%	20.22%	13.2%	8.61%	8.41%	5.06%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Coopervision	1.58B	-	1.88B	1.97B	1.84B	2.15B	2.24B	2.42B	2.61B	2.74B
Coopervision Growth	-	-	-	4.83%	-6.58%	16.77%	4.24%	8.04%	7.66%	5.15%
Coopersurgical	389.6M	-	650.8M	680.5M	587.9M	770.5M	1.07B	1.17B	1.29B	1.35B
Coopersurgical Growth	-	-	-	4.56%	-13.61%	31.06%	38.23%	9.80%	9.96%	4.87%
Coopersurgical	-	464.9M	-	-	-	-	-	-	-	-
Coopersurgical Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	1.14B	1.19B	1.44B	-	1.5B	1.83B	2.15B	2.38B	2.57B	2.73B
UNITED STATES Growth	-	4.00%	21.04%	-	-	22.66%	17.38%	10.33%	8.15%	6.39%
Europe	1.15B	1.19B	1.25B	1.16B	1.12B	1.77B	1.88B	2.06B	2.22B	2.38B
Europe Growth	-	3.62%	5.64%	-7.82%	-3.35%	58.74%	6.29%	9.20%	7.93%	7.06%
Rest Of World, Excluding United States And Europe	-	-	-	-	537.5M	625.4M	682.7M	-	773.6M	785.2M
Rest Of World, Excluding United States And Europe Growth	-	-	-	-	-	16.35%	9.16%	-	-	1.50%
Rest Of World Other Eliminations And Corporate	-	-	-157.3M	-364.7M	-	-	-	-	-	-
Rest Of World Other Eliminations And Corporate Growth	-	-	-	-131.85%	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

The Cooper Companies, Inc. (COO) has a price-to-earnings (P/E) ratio of 44.0x. This suggests investors expect higher future growth.

Growth & Financials

The Cooper Companies, Inc. (COO) reported $4.05B in revenue for fiscal year 2025. This represents a 180% increase from $1.45B in 2012.

The Cooper Companies, Inc. (COO) grew revenue by 5.1% over the past year. This is steady growth.

Yes, The Cooper Companies, Inc. (COO) is profitable, generating $407.8M in net income for fiscal year 2025 (9.2% net margin).

Dividend & Returns

The Cooper Companies, Inc. (COO) has a return on equity (ROE) of 4.6%. This is below average, suggesting room for improvement.

The Cooper Companies, Inc. (COO) generated $411.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...